EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma-Reference-Cited by-同舟云学术

EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma

Published:2023-08-02 Issue:9 Volume:37 Page:1925-1928
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Chemlal Djamila,Varlet Emmanuel,Machura Amelie,Ovejero Sara,Requirand Guilhem,Robert Nicolas,Cartron Guillaume,Alaterre Elina,Bret Caroline,Vincent Laure^ORCID,Herbaux Charles^ORCID,Cavalli Giacomo^ORCID,Bruyer Angélique,De Boussac Hugues,Moreaux Jerome^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-023-01983-0.pdf

Reference16 articles.

1. van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410–27.

2. Yamamoto C, Minakata D, Koyama S, Sekiguchi K, Fukui Y, Murahashi R, et al. Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma. Blood. 2022;140:594–607.

3. Lee HC. Structure and enzymatic functions of human CD38. Mol Med. 2006;12:317–23.

4. van de Donk NW, Janmaat ML, Mutis T, Lammerts van Bueren JJ, Ahmadi T, Sasser AK, et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev. 2016;270:95–112.

5. Saltarella I, Desantis V, Melaccio A, Solimando AG, Lamanuzzi A, Ria R, et al. Mechanisms of resistance to anti-CD38 daratumumab in multiple myeloma. Cells. 2020;9:167.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transient loss of Polycomb components induces an epigenetic cancer fate;Nature;2024-04-24

2. CD56 expression predicts response to Daratumumab-based regimens;Blood Cancer Journal;2024-04-12

3. Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors;Leukemia;2024-03-16